SAN DIEGO, March 19, 2024 /PRNewswire/ -- Poseida
Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell and gene
therapy company advancing a new class of treatments for patients
with cancer and rare diseases, today announced that the Company's
President and Chief Executive Officer, Kristin Yarema, Ph.D., will participate in a
virtual fireside chat at the H.C. Wainwright 2nd Annual
Cell Therapy Virtual Conference on Tuesday,
March 26, 2024 at 1:00pm PT |
4:00pm ET.
A live webcast of the fireside chat will be available on the
Investors & Media Section of Poseida's website,
www.poseida.com. A replay of the webcast will be available for
approximately 90 days following the presentation.
About Poseida Therapeutics, Inc.
Poseida Therapeutics
is a clinical-stage biopharmaceutical company advancing
differentiated cell and gene therapies with the capacity to cure
certain cancers and rare diseases. The Company's pipeline includes
allogeneic CAR-T cell therapy product candidates for both solid and
liquid tumors as well as in vivo gene therapy product candidates
that address patient populations with high unmet medical need. The
Company's approach to cell and gene therapies is based on its
proprietary genetic editing platforms, including its non-viral
piggyBac® DNA Delivery System, Cas-CLOVER™ Site-Specific
Gene Editing System, Booster Molecule, and nanoparticle and hybrid
gene delivery technologies as well as in-house GMP cell therapy
manufacturing. The Company has formed a global strategic
collaboration with Roche to unlock the promise of cell therapies
for patients with hematological malignancies. Learn more at
www.poseida.com and connect with Poseida on X and
LinkedIn.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/poseida-therapeutics-to-present-at-hc-wainwright-2nd-annual-cell-therapy-virtual-conference-302092083.html
SOURCE Poseida Therapeutics, Inc.
